Plasma markers for colorectal cancer diagnosis or prognosis and use thereof

By detecting the expression level of eRNA58712 in plasma, a non-invasive and precise diagnostic method for colorectal cancer has been developed, which solves the problems of high invasiveness and narrow diagnostic range in existing technologies and realizes the potential for early identification and personalized treatment.

CN119193830BActive Publication Date: 2026-06-19NINGBO MEDICAL CENT LIHUILI HOSPITACL
View PDF 3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
NINGBO MEDICAL CENT LIHUILI HOSPITACL
Filing Date
2024-09-24
Publication Date
2026-06-19

AI Technical Summary

Technical Problem

Existing diagnostic methods for colorectal cancer, such as colonoscopy, fecal occult blood test, and virtual colonoscopy, are invasive, complex, and costly. Furthermore, existing biomarkers, such as SNP sites, have a narrow diagnostic range and cannot be applied to all patients.

Method used

Using a specific enhancer RNA (eRNA58712) in plasma as a biomarker, we can detect its expression level and perform qRT-PCR using primer combinations to develop a diagnostic kit and targeted drugs for colorectal cancer, achieving non-invasive and accurate early diagnosis.

Benefits of technology

It enables rapid and accurate early identification of colorectal cancer, improves diagnostic precision and patient comfort, reduces medical costs, and provides reference information for personalized treatment plans.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119193830B_ABST
    Figure CN119193830B_ABST
Patent Text Reader

Abstract

This invention belongs to the field of biotechnology and relates to a plasma biomarker for the diagnosis or prediction of colorectal cancer and its application. This invention pioneers the application of a specific enhancer RNA (eRNA58712) in serum for the early diagnosis or detection of colorectal cancer, marking a significant advancement in the search for novel biomarkers. This invention utilizes the fact that the expression level of eRNA58712 in the serum of colorectal cancer patients is significantly higher than that in healthy individuals, and that its expression level is significantly positively correlated with the occurrence and development of colorectal cancer. This means that by measuring the concentration of eRNA58712 in blood samples, rapid and accurate early identification of colorectal cancer can be achieved at the molecular level.
Need to check novelty before this filing date? Find Prior Art